Unit of Endocrinology, Diabetology and Nutrition, Jean Verdier Hospital, CINFO, CRNH-IdF, AP-HP, Paris Nord University, Avenue du 14 Juillet, 93140, Bondy, France.
Cardiovasc Diabetol. 2021 Aug 19;20(1):170. doi: 10.1186/s12933-021-01356-w.
The incidence and prevalence of hypertension is increasing worldwide, with approximately 1.13 billion of people currently affected by the disease, often in association with other diseases such as diabetes mellitus, chronic kidney disease, dyslipidemia/hypercholesterolemia, and obesity. The autonomic nervous system has been implicated in the pathophysiology of hypertension, and treatments targeting the sympathetic nervous system (SNS), a key component of the autonomic nervous system, have been developed; however, current recommendations provide little guidance on their use. This review discusses the etiology of hypertension, and more specifically the role of the SNS in the pathophysiology of hypertension and its associated disorders. In addition, the effects of current antihypertensive management strategies, including pharmacotherapies, on the SNS are examined, with a focus on imidazoline receptor agonists.
高血压的发病率和患病率在全球范围内不断上升,目前约有 11.3 亿人受到该疾病的影响,通常与其他疾病如糖尿病、慢性肾病、血脂异常/高胆固醇血症和肥胖症等相关。自主神经系统与高血压的病理生理学有关,并且已经开发出针对自主神经系统(SNS)的治疗方法,SNS 是自主神经系统的关键组成部分;然而,目前的建议几乎没有提供关于其使用的指导。本综述讨论了高血压的病因,更具体地说,讨论了 SNS 在高血压及其相关疾病的病理生理学中的作用。此外,还检查了当前抗高血压管理策略(包括药物治疗)对 SNS 的影响,重点是咪唑啉受体激动剂。